ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO786

Risks Associated With Low eGFRcr, eGFRcys, and eGFRcr-cys at Older Age

Session Information

Category: Geriatric Nephrology

  • 1200 Geriatric Nephrology

Authors

  • Fu, Edouard, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Carrero, Juan Jesus, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Sang, Yingying, Johns Hopkins University, Baltimore, Maryland, United States
  • Evans, Marie, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Ballew, Shoshana, Johns Hopkins University, Baltimore, Maryland, United States
  • Inker, Lesley Ann, Tufts Medical Center, Boston, Massachusetts, United States
  • Grams, Morgan, Johns Hopkins University, Baltimore, Maryland, United States
  • Levey, Andrew S., Tufts Medical Center, Boston, Massachusetts, United States
  • Coresh, Josef, Johns Hopkins University, Baltimore, Maryland, United States
Background

Understanding the risk consequences of CKD at older age has often been limited to kidney failure replacement therapy (KFRT) and all-cause mortality (ACM), and to GFR estimated using serum creatinine (eGFRcr). However, eGFRcr may be falsely elevated in the elderly due to low muscle mass. We sought to compare the risks of several clinically relevant outcomes associated with both eGFRcr and cystatin C-based eGFR (unrelated to muscle mass), in elderly patients in routine health care.

Methods

We included all 79,995 patients (mean age 77 years, 50% female) in Stockholm region, Sweden (SCREAM) age 65+ years who undertook routine outpatient tests of IDMS calibrated creatinine and cystatin C on the same day during 2011-2018. We modeled CKD-EPI eGFR using creatinine (eGFRcr), cystatin C (eGFRcys) or both (eGFRcr-cys) as a spline in adjusted negative binomial and Cox regressions of subsequent risk for 7 clinical outcomes: acute kidney injury, KFRT, any hospitalization, heart failure hospitalization, major adverse cardiovascular events, cardiovascular and all-cause mortality.

Results

22% of older adults with creatinine testing also had routine cystatin C measurements. Figure 1 shows the HRs for each outcome at eGFR 30 or 60 vs. 80 ml/min/1.73m2 by age group. Overall, eGFRcr was not as consistently associated across the range of outcomes as eGFRcys or eGFRcr-cys, especially at greater age. A U-shaped relationship was observed for all-cause mortality, cardiovascular mortality and hospitalization for eGFRcr, but not for eGFRcys or eGFRcr-cys (Figure 2).

Conclusion

eGFRcys and eGFRcr-cys reveal risk associations which are missed by eGFRcr. The U-shaped relationship with eGFRcr, not seen for eGFRcys, suggests the increased risk at high eGFRcr is associated with low creatinine generation, not true high GFR. Looking at outcomes beyond KFRT and mortality and using cystatin C allows for a better understanding of risks in CKD.